Scientists are making inroads because thousands of people with Parkinson’s and their family members have donated their brains to science, including to PDF-supported programs at Columbia University Medical Center and Rush University Medical Center.
PDF Grant Programs
Are you interested in furthering Parkinson's science? View PDF's open grant programs.
Targeting the Intrinsically Disordered Structural Ensemble of ?-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson's Disease.
PDF's targeted PubMed search provides you with access to journal articles from the last 90 days that may be pertinent to Parkinson's disease research.
Not what you're looking for? Do you need informational publications about Parkinson's targeted for people living with Parkinson's, caregivers and family members? Please browse PDF's educational materials and programs - which are all available electronically or in print. Order for yourself, a loved one or in bulk for your patients or support group.
PLoS One 2014 ; 9(2):e87133
Authors: Gergely Tůth, Shyra J Gardai, Wagner Zago, Carlos W Bertoncini, Nunilo Cremades, Susan L Roy, Mitali A Tambe, Jean-Christophe Rochet, Celine Galvagnion, Gaia Skibinski, Steven Finkbeiner, Michael Bova, Karin Regnstrom, San-San Chiou, Jennifer Johnston, Kari Callaway, John P Anderson, Michael F Jobling, Alexander K Buell, Ted A Yednock, Tuomas P J Knowles, Michele Vendruscolo, John Christodoulou, Christopher M Dobson, Dale Schenk, Lisa McConlogue
The misfolding of intrinsically disordered proteins such as ?-synuclein, tau and the A? peptide has been associated with many highly debilitating neurodegenerative syndromes including Parkinson's and Alzheimer's diseases. Therapeutic targeting of the monomeric state of such intrinsically disordered proteins by small molecules has, however, been a major challenge because of their heterogeneous conformational properties. We show here that a combination of computational and experimental techniques has led to the identification of a drug-like phenyl-sulfonamide compound (ELN484228), that targets ?-synuclein, a key protein in Parkinson's disease. We found that this compound has substantial biological activity in cellular models of ?-synuclein-mediated dysfunction, including rescue of ?-synuclein-induced disruption of vesicle trafficking and dopaminergic neuronal loss and neurite retraction most likely by reducing the amount of ?-synuclein targeted to sites of vesicle mobilization such as the synapse in neurons or the site of bead engulfment in microglial cells. These results indicate that targeting ?-synuclein by small molecules represents a promising approach to the development of therapeutic treatments of Parkinson's disease and related conditions.
PMID: 24551051 [PubMed - as supplied by publisher]